Akwasi Opoku BA, Kenneth Iwuji MD, Brendon Clough PharmD, Jacqueline Le PharmD, McKenzie Moore PharmD, Chelsi Simmons PharmD, Bridget Hyde PharmD
Heparin, one of the world’s oldest anticoagulation medications, accelerates the rate of inhibition of previously activated clotting factors. It is most often used in the prophylaxis and treatment of thromboembolic disorders and complications associated with atrial fibrillation. The two most common ways to monitor plasma heparin levels and anticoagulation therapy are the activated partial thromboplastin time (aPTT) and anti-factor Xa assay (anti-Xa). This article assesses the performance of aPTT and anti-Xa monitoring protocols and analyzes the discordance between aPTT and anti-Xa levels and its clinical implications in patients receiving intravenous heparin therapy.
Keywords: unfractionated heparin, heparin, aPTT, anti-factor Xa, discordance, clotting
Article citation: Opoku A, Iwuji K, Clough B, Le J, Moore M, Simmons C, Hyde B. Discordance between aPTT and anti-factor Xa levels and implications in patients receiving intravenous unfractionated heparin therapy. The Southwest Respiratory and Critical Care Chronicles 2019;7(30):12–18
From: Department of Internal Medicine (KI), The School of Medicine (AO, BC), and the School of Pharmacy (JL, MM, CS, BH), Texas Tech University Health Sciences Center, Lubbock, Texas
Reviewer: Victor Test MD
Conflicts of interest: none
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.